Background. The prognosis of glioblastoma multiforme remains poor despite recent therapeutic advances. Several clinical and therapeutic factors as well as tumour characteristics have been reported as significant to survival. A more efficient determination of the prognostic factors is required to optimize individual therapeutic management. The aim of our study was to evaluate by univariate then multivariate analysis the factors that influence prognosis and particularly survival.
Methods. Data of 340 patients with newly-diagnosed GBM were retrospectively analyzed. Univariate analysis of prognosis factors of survival time was performed. Factors that seemed determinant were evaluated by Kaplan–Meier survival curves. Finally, the significant factors found in univariate analysis were tested in multivariate analysis using the COX regression method.
Findings. Using multivariate analysis, the following factors were found to influence survival: radiotherapy was the predominant factor followed by radical surgery, tumour location, age and chemotherapy. Patients treated with temozolomide had a markedly better survival rate than patients treated with other chemotherapies (Log-rank test P < 0.005). The values of GBM type (de novo or secondary), as well as repeated surgery and partial surgery (vs. simple biopsy) were suggested by univariate analysis but not confirmed by the COX regression method. After radical surgery, progression-free survival was correlated to overall survival (r = 0.87, P < 10e-5).
Conclusions. The influence of radiotherapy on survival was greater than the influence of age, an argument supporting the proposition of radiotherapy for patients until at least age 70. In the case of recurrence, the correlation between overall survival and progression-free survival is an important factor when considering the therapeutic options. Initial radical surgery and repeated procedures dramatically influence survival. The benefit of partial surgery remains difficult to evaluate. Partial surgery could be used to decrease intracranial pressure and to minimize residual tumours in order to enable treatment by chemotherapy and radiotherapy. The value of temozolomide treatment was confirmed.
Albert, FK, Forsting, M, Sartor, K, Adams, HP, Kunse, S 1994Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosisNeurosurgery344561PubMedCrossRefGoogle Scholar
Bussiere, M, Hopman, W, Day, A, Pombo, AP, Neves, T, Espinosa, F 2005Indicators of functional status for primary malignant brain tumor patientsCan J Neurol Sci325056PubMedGoogle Scholar
Cox, DR 1972Regression models and life tablesJ R Stat Soc B34187220Google Scholar
Daumas-Duport, C, Scheithauer, B, O’Fallon, J, Kelly, P 1988Grading of astrocytomas. A simple and reproducible methodCancer6221522165PubMedCrossRefGoogle Scholar
Devaux, BC, O’Fallon, JR, Kelly, PJ 1993Resection, biopsy and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcomeJ Neurosurg78767775PubMedGoogle Scholar
Fujisawa, H, Reis, RM, Nakamura, M, Colella, S, Yonekawa, Y, Kleihues, P, Ohgaki, H 2000Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomasLab Invest806571PubMedCrossRefGoogle Scholar
Hegi, ME, Diserens, AC, Gorlia, T, Hamou, MF, De Tribolet, N, Weller, M, Kros, JM, Hainfeller, JA, Mason, W, Mariani, L, Bromberg, JE, Hau, P, Mirimanoff, RO, Cairncross, JG, Janser, RC, Stupp, R 2005MGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med3529971003PubMedCrossRefGoogle Scholar
Hiesiger, EM, Hayes, RL, Pierz, DM, Budzilovich, GN 1993Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomasJ Neurooncol1693104PubMedCrossRefGoogle Scholar
Kaplan, EL, Meier, P 1958Non parametric estimation from incomplete observationsJ Am Stat Assoc53457481CrossRefGoogle Scholar
Keles, GE, Anderson, B, Berger, MS 1999The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphereSurg Neurol52371379PubMedCrossRefGoogle Scholar
Kleihues, P, Cavenee, WK 2000Pathology and genetic of tumors of the nervous system: World Health Organization Classification of tumorsIARC PressLyon, France5569Google Scholar
Kleihues, P, Ohgaki, H 1999Primary and secondary glioblastomas: from concept to clinical diagnosisNeuro-Oncology14451PubMedCrossRefGoogle Scholar
Lacroix, M, Abi-Said, D, Fourney, DR, Gokaslan, ZL, Shi, W, Demonte, F, Lang, FF, McCutcheon, IE, Hassenbusch, SJ, Holland, E, Hess, K, Michael, C, Miller, D, Sawaya, R 2001A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extend of resection of resection and survivalJ Neurosurg95190198PubMedGoogle Scholar
Lang, FF, Miller, DC, Koslow, M, Newcomb, EW 1994Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumorsJ Neurosurg81427436PubMedGoogle Scholar
Mangiola, A, Maira, G, De Bonis, P, Porso, P, Pettorini, B, Sabatino, G, Anile, C 2006Glioblastoma multiforme in the elderly: a therapeutic challengeJ Neurooncol76159163PubMedCrossRefGoogle Scholar
Mineo, JF, Quintin-Roue, I, Lucas, B, Buburuzan, V, Besson, G 2002Glioblastomas: clinical study and prognosis factorsNeurochirurgie48500509PubMedGoogle Scholar
Mineo, JF, Bordron, A, Quintin-Roué, I, Loisel, S, Le Ster, K, Buhé, V, Lagarde, N, Berthou, C 2004Recombinant Humanized Anti-HER2/neu Antibody (Herceptin®) induces cellular death of glioblastomasBr J Cancer9111951199PubMedGoogle Scholar
Nozaki, M, Tada, M, Kobayashi, H, Zhang, CL, Sawamura, Y, Abe, H, Ishii, N, Van Meir, EG 1999Roles of the functional loss of P53 and other genes in astrocytoma tumorigenesis and progressionNeuro-Oncology1124137PubMedGoogle Scholar
Obwegeser, A, Ortler, M, Seiwald, M, Ulmer, H, Kostron, H 1995Therapy of glioblastoma multiforme: a cumulative experience of 10 yearsActa Neurochir (Wien)1372933CrossRefGoogle Scholar
Polin, RS, Marko, NF, Ammerman, MD, Shaffrey, ME, Huang, W, Anderson, FA,Jr, Caputy, AJ, Laws, ER 2005Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheresJ Neurosurg102276283PubMedGoogle Scholar
Puzzilli, F, Ruggeri, A, Mastronardi, L, Di Stephano, D, Lunardi, P 1998Long-term survival in cerebral glioblastoma. Case report and critical review of the literatureTumori846974PubMedGoogle Scholar
Rainov, NG, Dobberstein, KU, Bahn, H, Holzhausen, HJ, Lautenschlager, C, Heideke, V, Burkert, W 1997Prognosis factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survivalJ Neurooncol351328PubMedCrossRefGoogle Scholar
Shinoda, J, Sakai, N, Murase, S, Yano, H, Matsuhisa, T, Funakoshi, T 2001Selection of eligible patients with supratentorial glioblastoma gross total resectionJ Neurooncol52161171PubMedCrossRefGoogle Scholar
Shrieve, DC, Alexander, E, Black, PM, Wen, PY, Fine, HA, Kooy, HM, Loeffler, JS 1999Treatment of patient with primary glioblastoma multiforme with standart postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcomeJ Neurosurg907277PubMedGoogle Scholar
Silbergeld, DL, Rostomily, RC, Alvord, EC,Jr1991The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adultsJ Neurooncol10179185PubMedCrossRefGoogle Scholar
Stark, AM, Nabavi, A, Mehdorn, HM, Blömer, U 2005Glioblastoma multiforme: report of 267 cases treated at a single institutionSurg Neurol63162169PubMedCrossRefGoogle Scholar
Stummer, W, Novotny, A, Stepp, H, Goetz, C, Bize, K, Reulen, HJ 2000Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid induced porphyrins: a prospective study of 52 consecutive patientsJ Neurosurg9310031013PubMedCrossRefGoogle Scholar
Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ, Belanger, K, Brandes, AA, Marosi, C, Bogdahn, U, Curshmann, J, Janzer, RC, Ludwin, SK, Gorlia, T, Allgeier, A, Lacombe, D, Cairncross, JG, Eisenhauer, E, Mirimanoff, RO 2005Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med352987996PubMedCrossRefGoogle Scholar
Tohma, Y, Gratas, C, Biernat, W, Peraud, A, Fukuda, M, Yonekawa, Y, Kleihues, P, Ohgaki, H 1998PTEN (MMAC1) Mutation are frequent in primary glioblastomas but not in secondary glioblastomasJ Neuropathol Exp Neurol57684689PubMedGoogle Scholar